- Walgreens Boots Alliance and Verily, a healthcare company owned by Google’s parent entity Alphabet, have announced a collaboration on multiple projects intended to improve chronic disease management and reduce healthcare spending.
Walgreens will be a first-choice retain pharmacy and commercialization partner for Verily, according to a press release.
The partnership will take a data-driven approach to exploring how emerging analytics technologies and strategies, as well as innovative sensors and Internet of Things devices, can foster better outcomes without adding to overall industry spending.
“We’re focused on finding innovative ways to deliver better patient care at lower costs, and working with the right healthcare partners to help bring new services and solutions to our patients and customers,” said Stefano Pessina, chief executive officer, Walgreens Boots Alliance, Inc.
“The continued rise in chronic diseases today can be costly to patients as well as to our healthcare system. Working with Verily, we’ll look at how we can best support integrated and value-based care to meet our patients’ needs, as well as opportunities to address other chronic conditions over time.”
The two companies will focus first on medication adherence, a multi-billion dollar problem that can reduce the effectiveness of chronic disease interventions. The pilot will utilize consumer-facing devices and other strategies intended to reduce non-adherence.
A second project, focused on diabetes management, will enlist the aid of Onduo, a joint venture between Verily and pharmaceutical giant Sanofi.
The virtual solution will offer tools, coaching, and remote care access to individuals with type 2 diabetes in an effort to improve self-management and contain unnecessary costs.
“We are well aligned with Walgreens on the need to develop and bring to market solutions that help people better engage with their health and manage their chronic conditions. This relationship affords us the opportunity to jointly tackle real-world issues that significantly impact the health of individuals and communities,” said Andrew Conrad, chief executive officer, Verily.
“Medication adherence, which represents one of the most significant and costly barriers to improving patient outcomes, is an area that I am most excited to work on with a partner like Walgreens.”